XBiotech Inc. (XBIT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98400H1023
XBiotech Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -55.69 m USD |
| EBIT | -45.31 m USD |
| Net income | -45.54 m USD |
| Diluted EPS – continuing operations | -1.49 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
More stocks
- Lingotes (LGT.MC)
- Young Shine Electric Co., Ltd. (2249.TWO)
- Taiwan Auto-Design Co. (6791.TWO)
- Hae In (003010.KS)
- Mitre Realty Empreendimentos e Participações S.A (MTRE3.SA)
- Arbe Robotics Ltd (ARBE)
- Kaulin Mfg (1531.TW)
- Permianville Royalty Trust (PVL)
- Majestic Gold Corp. (MJS.V)
- Aker Technology Co Ltd (6174.TWO)
- CitroTech Inc. (CITR)
- Seco/Warwick SA (SWG.WA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.